Clinical trial Voyager
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
| Cancers | |
|---|---|
| Organ | Gastrointestinal stromal tumors (GIST) |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Blueprint Medicines Corporation |
| EudraCT Identifier | 2017-003497-14 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03465722 |
| Inclusion criteria | "3rd line metastatic " |
| Last update |